IOL Chemicals & Pharmaceuticals Ltd. (IOLCP) AI Stock Analysis

• Market Cap: ₹21.80B
• Dividend Yield: 0.97%
• Average Volume (3M): 113.78K
• Price to Earnings (P/E): 29.4
• Beta (1Y): 1.75
• Revenue Growth: 5.74%
• EPS Growth: 16.06%
• Country: IN
• Employees: 2,777
• Sector: Basic Materials
• Sector Strength: 58
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 1.10
• Shares Outstanding: 293,527,500
• 10 Day Avg. Volume: 248,884
• 30 Day Avg. Volume: 113,785
• PEG Ratio: -3.72
• Price to Book (P/B): 5.55
• Price to Sales (P/S): 4.53
• P/FCF Ratio: -268.11
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): 4.6
• Revenue Forecast (FY): ₹23.14B

• Rating: 60 Neutral
• Price Target: ₹78.00 ▼(-7.24% Downside)
• Action: Reiterated Date: 11/13/25
• Date: Action: Reiterated 11/13/25

The overall stock score of 60 reflects a stable financial position with a strong balance sheet, but challenges in revenue growth and cash flow optimization. Technical indicators suggest a bearish trend, and the valuation indicates moderate pricing with limited dividend income potential. The absence of recent earnings call data or notable corporate events leaves these areas unassessed.

Positive Factors

Balance Sheet Strength

A strong balance sheet with low leverage provides durable financial flexibility: it supports sustained capex or debottlenecking, helps absorb demand cyclicality in APIs/chemicals, and reduces refinancing risk, enabling long-term investment in capacity and R&D.

Market Position in APIs

A notable position in ibuprofen and related intermediates indicates specialized capabilities and established customer relationships. This focused product strength supports stable B2B demand, export diversification, and pricing leverage versus commodity peers over the medium term.

Positive Revenue Trend

Reported revenue growth of ~8.4% signals ongoing demand expansion or market share gains. Sustained topline growth underpins capacity utilization, helps spread fixed costs, and creates scope to improve margins and fund strategic initiatives without over-relying on external financing.

Negative Factors

Declining Free Cash Flow

A decline in free cash flow constrains the company’s ability to fund capex, deleverage, or return capital to shareholders. Over months this can limit strategic investments, reduce buffer for raw-material volatility, and increase reliance on external funding for growth projects.

Margin and Revenue Pressure

Falling revenue coupled with compression in EBIT/EBITDA margins points to operating efficiency pressures or adverse pricing/input-cost dynamics. If structural, these trends can reduce reinvestment capacity, weaken competitive positioning, and slow recovery of profitability.

Weaker Return on Equity

A declining return on equity signals the company is generating lower shareholder returns from its capital base. Persistently lower ROE can indicate suboptimal capital allocation, reduced profitability, or rising working capital needs, impacting long-term investor returns.

IOL Chemicals & Pharmaceuticals Ltd. Business Overview & Revenue Model

Company Description

IOL Chemicals and Pharmaceuticals Limited manufactures and sells pharmaceutical and chemical products in India and internationally. The company offers active pharmaceutical ingredients (API), such as ibuprofen, ibuprofen lysinate, ibuprofen sodium, and dex- ibuprofen; and other APIs, including metformin hydrochloride, clopidogrel bisulphate, pantoprazole sodium, ursodeoxycholic acid, losartan potassium, gabapentin, levetiracetam, lamotrigine, and fenofibrate. Its products are used for treatments, which include anti-inflammatory, analgesic and antipyretic, anti-diabetic, anti- platelet, anti-cholesterol, anti- convulsant, anti-cholelithic, as well as proton pump inhibitor. The company also provides specialty industrial chemicals comprising ethyl acetate, iso butyl benzene, acetyl chloride, and mono chloro acetic acid for use in food processing, flexible packaging, pharmaceuticals, textiles, ink, paint, pesticides, and chemical intermediates industries. IOL Chemicals and Pharmaceuticals Limited was incorporated in 1986 and is headquartered in Ludhiana, India.

How the Company Makes Money

IOLCP primarily makes money by manufacturing and selling (1) pharmaceutical APIs—most notably ibuprofen—along with other APIs/intermediates, and (2) specialty/industrial chemicals and chemical intermediates. Revenue is generated through business-to-business sales to pharmaceutical formulators, generic-drug companies, contract manufacturers, and chemical industry customers, both in India and export markets. Earnings are driven by sales volumes and realized prices for APIs/chemicals, the product mix (higher-margin APIs vs. lower-margin commodity-like chemicals), and the spread between selling prices and input costs for key raw materials and utilities. The company’s profitability can be influenced by demand cycles in the ibuprofen/API market, competitive dynamics, capacity utilization, and changes in raw-material and energy prices. Specific details on major customer concentration, named long-term partnerships, or contract structures are not available in the provided context; therefore: null.

IOL Chemicals & Pharmaceuticals Ltd. Financial Statement Overview

Summary

IOL Chemicals & Pharmaceuticals Ltd. presents a stable financial position with a robust balance sheet and prudent leverage. However, challenges are evident in maintaining revenue growth and optimizing cash flow. Continued focus on improving profitability and cash management is essential to support long-term growth.

Income Statement

The company shows modest profitability with a consistent gross profit margin and net profit margin over the years. However, there is a recent decline in revenue, reflecting a potential challenge in sustaining growth. The EBIT and EBITDA margins have also decreased, indicating pressure on operating efficiency.

Balance Sheet

The balance sheet is strong with a healthy equity ratio and low leverage, indicating financial stability. The company's debt-to-equity ratio is favorable, reflecting prudent financial management. However, the return on equity has decreased, suggesting a need for improved profitability to enhance shareholder returns.

Cash Flow

The cash flow analysis indicates a decline in free cash flow, which may affect future investment capabilities. The operating cash flow is positive, but the free cash flow to net income ratio is concerning, suggesting potential inefficiencies in cash management.

Breakdown	TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	21.70B	20.68B	21.19B	22.02B	21.84B	19.46B
Gross Profit	7.38B	6.54B	2.70B	6.41B	5.72B	8.22B
EBITDA	2.52B	2.25B	2.61B	2.46B	2.71B	6.11B
Net Income	1.16B	1.01B	1.34B	1.39B	1.68B	4.45B
Balance Sheet
Total Assets	24.13B	23.82B	22.44B	20.22B	19.62B	16.10B
Cash, Cash Equivalents and Short-Term Investments	1.79B	2.09B	1.43B	186.40M	1.20B	3.37B
Total Debt	1.59B	1.17B	327.60M	798.10M	439.50M	27.30M
Total Liabilities	6.62B	6.94B	6.33B	5.14B	5.70B	3.50B
Stockholders Equity	17.51B	16.88B	16.12B	15.08B	13.92B	12.60B
Cash Flow
Free Cash Flow	-535.70M	-349.30M	159.10M	-895.50M	-602.40M	2.72B
Operating Cash Flow	110.60M	1.79B	2.90B	1.22B	930.50M	3.80B
Investing Cash Flow	-961.60M	-1.54B	-1.91B	-1.20B	-1.21B	-3.17B
Financing Cash Flow	342.30M	460.40M	-925.00M	-41.10M	-16.40M	-582.80M

IOL Chemicals & Pharmaceuticals Ltd. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 84.09
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:IOLCP, the sentiment is Positive. The current price of 84.09 is above the 20-day moving average (MA) of 71.95, above the 50-day MA of 73.19, and below the 200-day MA of 88.17, indicating a neutral trend. The MACD of -0.59 indicates Negative momentum. The RSI at 54.29 is Neutral, neither overbought nor oversold. The STOCH value of 76.22 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:IOLCP.

IOL Chemicals & Pharmaceuticals Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ROSSARI	64 Neutral	₹22.71B	24.59	―	0.09%	15.47%	-1.72%
Sector *	61 Neutral	$10.43B	7.12	-0.05%	2.87%	2.86%	-36.73%
IOLCP	60 Neutral	₹21.80B	29.38	―	0.97%	5.74%	16.06%
TATVA	53 Neutral	₹26.37B	51.39	―	0.07%	16.88%	0.69%
PRINCEPIPE	51 Neutral	₹26.53B	-310.89	―	0.20%	-4.37%	-82.37%
FAIRCHEMOR	47 Neutral	₹6.21B	-2,425.33	―	1.07%	-22.10%	-85.56%
TIRUMALCHM	45 Neutral	₹20.97B	-15.05	―	0.43%	-11.11%	-340.74%

IOL Chemicals & Pharmaceuticals Ltd. Corporate Events

IOL Chemicals & Pharmaceuticals Promoter Group Ups Stake Via Market Purchase

IOL Chemicals & Pharmaceuticals Ltd. disclosed that promoter group entity NCVI Enterprises Ltd. has increased its shareholding in the company through an on-market purchase. NCVI acquired 404,305 equity shares on 19 March 2026, raising its stake from 16.44% to 16.58%, in compliance with continual disclosure requirements under SEBI’s Prohibition of Insider Trading Regulations, 2015.

The filing underscores ongoing promoter interest and participation in the company’s equity, which may be interpreted by investors as a sign of confidence in IOL Chemicals & Pharmaceuticals’ prospects. The timely disclosure also highlights the company’s adherence to Indian securities regulations and governance norms, which is relevant for minority shareholders and market regulators.

IOL Chemicals & Pharmaceuticals Promoter Group Raises Stake via Market Purchase

IOL Chemicals and Pharmaceuticals Ltd. has disclosed a change in shareholding by promoter group entity NCVI Enterprises Ltd. under Regulation 7(2) of SEBI’s Prohibition of Insider Trading Regulations, 2015. The filing shows that NCVI Enterprises increased its equity stake through an on-market purchase, modestly raising the promoter group’s shareholding and signaling continued promoter commitment while underscoring the company’s adherence to mandated disclosure norms.

According to the disclosure, NCVI Enterprises acquired 700,000 equity shares on March 18, 2026, lifting its holding from about 16.20% to 16.44% of the company’s equity capital. This incremental increase in promoter ownership may be viewed positively by investors as a sign of confidence in the company’s prospects and reinforces transparency in governance through timely regulatory reporting to the stock exchanges.

IOL Chemicals & Pharmaceuticals Defends Compliance of Q3 FY2025 Financial Results

IOL Chemicals & Pharmaceuticals has clarified to the National Stock Exchange that its standalone and consolidated financial results for the quarter ended 31 December 2025 were prepared in full compliance with Indian Accounting Standards and the format prescribed under Schedule III of the Companies Act. The company addressed concerns that the submitted Q3 figures were not in the correct format and that standalone and consolidated numbers appeared identical.

Management explained that the close similarity in standalone and consolidated figures reflects the fact that, apart from one Section 8 subsidiary, its subsidiaries had not commenced business operations during the reporting period, resulting in only limited differences in profit, depreciation, and other expenses. IOL Chemicals & Pharmaceuticals has requested that the exchange accept and take on record the previously filed Q3 results as valid and compliant, aiming to dispel any doubts over its financial disclosure practices.